Skip to content
Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.
  • Insights
    • All Insights
    • 2023 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
  • Insights
    • All Insights
    • 2023 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe

Latest News

Explore more
Psychedelic Bulletin 182

Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding

December 10, 2024
Inside the FDA’s Psychedelics Journey- Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field

Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field

December 5, 2024
Psychedelic Drug Development Under Trump 2.0

Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future

November 30, 2024
Concerned Psychedelic Investor Survey Q3 2024

Q3’24 Survey: What are Psychedelics Investors Concerned About?

November 27, 2024
Interviews: Meet the Team Who Challenged the DEA on DOI and DOC

Interviews: Meet the Team Who Challenged the DEA on DOI and DOC

November 26, 2024
Q3'24 Survey: What are Psychedelics Investors Excited About?

Q3’24 Survey: What are Psychedelics Investors Excited About?

November 25, 2024

Pα+ Psychedelic Bulletin #181: Last-Minute Changes to Colorado’s Psychedelics Rules; Cybin’s Impressive 12-Month Data Overshadowed by Small N and Controversial Marketing Move

November 22, 2024
Psychedelic Investor Survey Q3 2024

Psychedelic Investor Survey Q3 2024

November 19, 2024
Explore more

Browse by Company

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2024, All Rights Reserved
  • Privacy Policy
  • Terms of Service